M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cryoablation for the Treatment of Metastatic Cancer

Not Applicable

Active, not recruiting

Conditions: Metastatic Malignant Neoplasm

Interventions: Procedure: Core Biopsy
Procedure: Cryosurgery
Drug: Immunotherapeutic Agent

First Posted Date: 2019-11-05

Last Posted Date: 2024-11-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT04150939

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Phase 1

Recruiting

Conditions: Refractory Acute Myeloid Leukemia
Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic/Myeloproliferative Neoplasm
Refractory Chronic Myelomonocytic Leukemia
Refractory Myelodysplastic/Myeloproliferative Neoplasm
Recurrent Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Drug: Gilteritinib
Drug: Venetoclax

First Posted Date: 2019-10-28

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 97

Registration Number: NCT04140487

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Transcranial Direct Current Stimulation in Reducing Pain in Cancer Patients With Chemotherapy Induced Peripheral Neuropathy

Early Phase 1

Withdrawn

Conditions: Chemotherapy-Induced Peripheral Neuropathy
Malignant Neoplasm

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Transcranial Direct Current Stimulation

First Posted Date: 2019-10-22

Last Posted Date: 2024-10-09

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04135326

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

Phase 4

Terminated

Conditions: Metastatic Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions: Procedure: Computed Tomography
Drug: Fluciclovine F18
Procedure: Positron Emission Tomography

First Posted Date: 2019-10-22

Last Posted Date: 2022-07-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT04134208

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions

Not Applicable

Completed

Conditions: Brain Neoplasm
Recurrent Malignant Brain Neoplasm
Lymphoma
Metastatic Malignant Neoplasm in the Brain

Interventions: Drug: Gadobenate Dimeglumine
Drug: Gadobutrol
Procedure: Magnetic Resonance Imaging

First Posted Date: 2019-10-21

Last Posted Date: 2022-11-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT04132843

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Binimetinib and Hydroxychloroquine in Treating Patients with KRAS Mutant Metastatic Pancreatic Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Pancreatic Adenocarcinoma
Stage IV Pancreatic Cancer AJCC V8

Interventions: Drug: Binimetinib
Drug: Hydroxychloroquine

First Posted Date: 2019-10-18

Last Posted Date: 2024-12-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT04132505

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease

Active, not recruiting

Conditions: Nonalcoholic Fatty Liver Disease
Physician

Interventions: Other: Interview
Other: Questionnaire Administration

First Posted Date: 2019-10-18

Last Posted Date: 2024-08-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 17

Registration Number: NCT04132440

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

Phase 2

Withdrawn

Conditions: Allogeneic Stem Cell Transplant Recipient
Hematopoietic and Lymphoid Cell Neoplasm
Hematologic and Lymphocytic Disorder

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Fludarabine
Drug: Itacitinib
Drug: Methotrexate
Drug: Tacrolimus

First Posted Date: 2019-10-16

Last Posted Date: 2020-10-29

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04127721

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

Phase 2

Recruiting

Conditions: Acute Biphenotypic Leukemia
T Acute Lymphoblastic Leukemia
Acute Bilineal Leukemia
Acute Myeloid Leukemia
Mixed Phenotype Acute Leukemia
Therapy-Related Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Drug: Venetoclax

First Posted Date: 2019-10-16

Last Posted Date: 2024-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 125

Registration Number: NCT04128501

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Phase 1

Recruiting

Conditions: Recurrent Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
High Risk Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome
Blasts More Than 10 Percent of Bone Marrow Nucleated Cells

Interventions: Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Drug: Quizartinib

First Posted Date: 2019-10-16

Last Posted Date: 2024-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 52

Registration Number: NCT04128748

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy